Hypertonie und Niere

Themenschwerpunkt

Zusammenfassung

Hypertonie und Proteinurie sind bekannte Risikofaktoren für kardiovaskuläre Morbidität und Mortalität, sowie für das Fortschreiten einer renalen Insuffizienz. Eine renale Funktionseinschränkung stellt ihrerseits einen wichtigen kardiovaskulären Risikofaktor dar. Eine konsequente antihypertensive und antiproteinurische Therapie kann wesentlich zur Prognoseverbesserung von betroffenen Patienten beitragen. Dieser Übersichtsartikel fasst bisher Bekanntes zur Rolle von Hypertonie und Proteinurie in Hinblick auf renale und kardiovaskuläre Prognose und die Vorteile einer konsequenten Therapie zusammen.

Schlüsselwörter

Hypertonie Proteinurie Niere Nierenfunktion 

Hypertension and the kidney

Summary

Hypertension and proteinuria are common risk factors for cardiovascular morbidity and mortality, as well as for the progression of renal disease. Renal functional impairment represents an independent cardiovascular risk factor by itself. Strict antihypertensive therapy and measures to maximally reduce proteinuria can substantially improve the prognosis of renal patients. This review summarizes current evidence for the role of hypertension and proteinuria with regard to renal and cardiovascular outcomes and for the importance of intensive antihypertensive and anti-proteinuric measures.

Keywords

Arterial hypertension Proteinuria Kidney Kidney function 

Literatur

  1. Ravera M, Re M, Deferrari L, Vettoretti S, Deferrari G. Importance of blood pressure control in chronic kidney disease. J Am Soc Nephrol, 17: S98–S103, 2006PubMedCrossRefGoogle Scholar
  2. Campese VM, Mitra N, Sandee D. Hypertension in renal parenchymal disease. Why is it so resistant to treatment? Kidney Int, 69: 967–973, 2006PubMedCrossRefGoogle Scholar
  3. Guyton AC, Coleman TG. Quantitative analysis of the pathophysiology of hypertension 1969. J Am Soc Nephrol, 10: 2248–2258, 1999PubMedGoogle Scholar
  4. Blankestijn PJ, Ligtenberg G, Klein IH, Koomans HA. Sympathetic overactivity in renal failure controlled by ACE inhibition: clinical significance. Nephrol Dial Transplant, 15: 755–758, 2000PubMedCrossRefGoogle Scholar
  5. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med, 327: 1912–1918, 1992PubMedGoogle Scholar
  6. Watschinger B, Habicht A. Renal sequelae of sympathetic hyperactivity. Wien Med Wochenschr 154(Spec No 1): 7–9, 2004PubMedGoogle Scholar
  7. Minutolo R, De Nicola L, Zamboli P, Chiodini P, Signoriello G, Toderico C, Arfe G, Boschi G, Brancati C, Iaccarino P, Conte G. Management of hypertension in patients with CKD: differences between primary and tertiary care settings. Am J Kidney Dis, 46: 18–25, 2005PubMedCrossRefGoogle Scholar
  8. Thanamayooran S, Rose C, Hirsch DJ. Effectiveness of a multidisciplinary kidney disease clinic in achieving treatment guideline targets. Nephrol Dial Transplant, 20: 2385–2393, 2005PubMedCrossRefGoogle Scholar
  9. Tonelli M, Gill J, Pandeya S, Bohm C, Levin A, Kiberd BA. Barriers to blood pressure control and angiotensin enzyme inhibitor use in Canadian patients with chronic renal insufficiency. Nephrol Dial Transplant, 17: 1426–1433, 2002PubMedCrossRefGoogle Scholar
  10. Ritz E. Renal dysfunction as a novel risk factor: microalbuminuria and cardiovascular risk. Kidney Int, 93(Suppl): S25–S28, 2005CrossRefGoogle Scholar
  11. Ritz E. Heart and kidney: fatal twins? Am J Med, 119: S31–S39, 2006PubMedCrossRefGoogle Scholar
  12. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation, 116: 85–97, 2007PubMedCrossRefGoogle Scholar
  13. Toto RD. Reducing cardiovascular events in high-risk patients: the challenge of managing hypertension in patients with diabetic renal disease. J Clin Hypertens (Greenwich), 9: 16–25, 2007Google Scholar
  14. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med, 334: 13–18, 1996PubMedCrossRefGoogle Scholar
  15. Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension, 41: 1341–1345, 2003PubMedCrossRefGoogle Scholar
  16. Rosario RF, Wesson DE. Primary hypertension and nephropathy. Curr Opin Nephrol Hy 15: 130–134, 2006CrossRefGoogle Scholar
  17. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension, 13: I80–I93, 1989PubMedGoogle Scholar
  18. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, Zanchetti A. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol, 12: 218–225, 2001PubMedGoogle Scholar
  19. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med, 134: 629–636, 2001PubMedGoogle Scholar
  20. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis, 43: S1–S290, 2004Google Scholar
  21. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med, 351: 1296–1305, 2004PubMedCrossRefGoogle Scholar
  22. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension, 42: 1050–1065, 2003PubMedCrossRefGoogle Scholar
  23. Sica D, Carl D. Pathologic basis and treatment considerations in chronic kidney disease-related hypertension. Semin Nephrol, 25: 246–251, 2005PubMedGoogle Scholar
  24. Wiederkehr M, Toto R, Fenves AZ, Ram CV. Hypertension and the kidney. Semin Nephrol, 25: 236–245, 2005PubMedGoogle Scholar
  25. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis, 32: S112–S119, 1998PubMedCrossRefGoogle Scholar
  26. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med, 339: 799–805, 1998PubMedCrossRefGoogle Scholar
  27. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int, 56: 2214–2219, 1999PubMedCrossRefGoogle Scholar
  28. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med, 139: 244–252, 2003PubMedGoogle Scholar
  29. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis, 48: 8–20, 2006PubMedCrossRefGoogle Scholar
  30. Palmer BF. Proteinuria as a therapeutic target in patients with chronic kidney disease. Am J Nephrol, 27: 287–293, 2007PubMedCrossRefGoogle Scholar
  31. Pinto-Sietsma SJ, Janssen WM, Hillege HL, Navis G, De Zeeuw D, De Jong PE. Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. J Am Soc Nephrol, 11: 1882–1888, 2000PubMedGoogle Scholar
  32. Cirillo M, Senigalliesi L, Laurenzi M, Alfieri R, Stamler J, Stamler R, Panarelli W, De Santo NG. Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: the gubbio population study. Arch Intern Med, 158: 1933–1939, 1998PubMedCrossRefGoogle Scholar
  33. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA, 288: 2421–2431, 2002PubMedCrossRefGoogle Scholar
  34. Warmoth L, Regalado MM, Simoni J, Harrist RB, Wesson DE. Cigarette smoking enhances increased urine albumin excretion as a risk factor for glomerular filtration rate decline in primary hypertension. Am J Med Sci, 330: 111–119, 2005PubMedCrossRefGoogle Scholar
  35. Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, DeFerrari G, Drury P, Locatelli F, Wiegmann TB, Lewis EJ. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis, 45: 281–287, 2005PubMedCrossRefGoogle Scholar
  36. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med, 123: 754–762, 1995PubMedGoogle Scholar
  37. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet, 349: 1857–1863, 1997CrossRefGoogle Scholar
  38. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int, 65: 2309–2320, 2004PubMedCrossRefGoogle Scholar
  39. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation, 106: 1777–1782, 2002PubMedCrossRefGoogle Scholar
  40. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, Levey AS. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med, 142: 342–351, 2005PubMedGoogle Scholar
  41. Deferrari G, Ravera M, Berruti V. Treatment of diabetic nephropathy in its early stages. Diabetes Metab Res Rev, 19: 101–114, 2003PubMedCrossRefGoogle Scholar
  42. Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore J, Jr., Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol, 16: 3027–3037, 2005PubMedCrossRefGoogle Scholar
  43. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 345: 861–869, 2001PubMedCrossRefGoogle Scholar
  44. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med, 329: 1456–1462, 1993PubMedCrossRefGoogle Scholar
  45. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 345: 851–860, 2001PubMedCrossRefGoogle Scholar
  46. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria [see comments]. Lancet, 354: 359–364, 1999PubMedCrossRefGoogle Scholar
  47. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med, 354: 131–140, 2006PubMedCrossRefGoogle Scholar
  48. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet, 366: 2026–2033, 2005PubMedCrossRefGoogle Scholar
  49. Griffin KA, Bidani AK. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. Clin J Am Soc Nephrol, 1: 1054–1065, 2006PubMedCrossRefGoogle Scholar
  50. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med, 165: 936–946, 2005PubMedCrossRefGoogle Scholar
  51. Culleton BF, Larson MG, Parfrey PS, Kannel WB, Levy D. Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study. Am J Med, 109: 1–8, 2000PubMedCrossRefGoogle Scholar
  52. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med, 165: 947–953, 2005PubMedCrossRefGoogle Scholar
  53. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis, 49: 12–26, 2007PubMedCrossRefGoogle Scholar
  54. Mann J, Gerstein H, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med, 134: 629–636, 2001PubMedGoogle Scholar
  55. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet, 362: 1527–1535, 2003PubMedCrossRefGoogle Scholar
  56. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Pohl M, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol, 16: 2170–2179, 2005PubMedCrossRefGoogle Scholar
  57. Anavekar NS, Gans DJ, Berl T, Rohde RD, Cooper W, Bhaumik A, Hunsicker LG, Rouleau JL, Lewis JB, Rosendorff C, Porush JG, Drury PL, Esmatjes E, Raz I, Vanhille P, Locatelli F, Goldhaber S, Lewis EJ, Pfeffer MA. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int, 92(Suppl): S50–S55, 2004CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Klinische Abteilung für Nephrologie und DialyseUniversitätsklinik für Innere Medizin III, Medizinische Universität WienWienAustria

Personalised recommendations